SEARCH

SEARCH BY CITATION

References

  • 1
    Lum BL & Torti FM. Adjuvant intravesical pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 1991; 83: 68294
  • 2
    Akaza H, Kurth KH, Williams R et al. Intravesical chemotherapy and immunotherapy for superficial tumours: Basic mechanism of action and future direction. Urol Oncol 1998; 4: 1219
  • 3
    Lobel B, Abbou C-C, Brausi MA et al. Guidelines for diagnosis, treatment, and follow-up of bladder cancer: The influence of prognostic factors and the significance of random biopsies. Urol Oncol 1998; 4: 94105
  • 4
    Morales A, Eidinger D, Bruce AW. Intracavity bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 1976; 137: 1803
  • 5
    Herr H & Intravesical BCG. Current results, natural history and implications for urothelial cancer prevention. J Cellular Biochem 1992; Suppl. 161: 1129
  • 6
    Lamm DL, Van De Meijden APM, Akaza H et al. Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995; 2 (Suppl. 2): 2335
  • 7
    Chopin D, Colombel H, Surig-Biscarat M et al. Resultat du traitement des tumeurs superficielles de la vessie par resection transurethrale seule et resection transurethrale suivie d'instillation endovesicale de bacille Calmette-Guerin. Ann Urol 1990; 24: 435440
  • 8
    Somogyi L, Szanto A, Polyak L, Baranyay F, Drinoczy M. BCG Immunotherapia a feluletes holyagtumorok adjuvans kezeleseben. Orvosi Hetilap 1993; 134: 18516
  • 9
    Ibrahiem El H, Gnoneim M, Nigam V, Brailovsky C, Elhilali M. Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumours: preliminary report. J Urol 1988; 140: 498500
  • 10
    Hall RR, Parmar MKB, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. Br Med J 1994; 308: 25760
  • 11
    Badalament RA, Herr H, Wong G et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. J Clin Oncol 1987; 5: 4419
  • 12
    Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomised multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996; 156: 9626
  • 13
    Lamm D. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 407
  • 14
    Pagano F, Bassi P, Milani C et al. Low-dose BCG therapy in superficial bladder cancer: a clinicopathological prospective study. In DeKernionJB, MazemanE eds, International Society of Urological Reports: Immunology of Urological Tumours. New York: Churchill Livingstone, 1990: 6981
  • 15
    Pinsky C, Camacho F, Kerr F et al. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: a report of a prospective, randomised trial. Cancer Treat Rep 1985; 69: 4753
  • 16
    Melekos M. Intravesical bacillus Calmette-Guerin prophylactic treatment for superficial bladder tumours: Results of a controlled prospective study. Urol Int 1990; 45: 13741
  • 17
    Yamamoto T, Hagiwara M, Nakazono M, Yamamoto H. Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Jap J Urol 1990; 81: 9971001
  • 18
    Bassi PF, Milani C, Meneghini A et al. BCG a baja dosis en la terapia de las neoplasias superficiales vesicales. Arch Esp Urol 1990; 42: 5037
  • 19
    Camacho F, Pinsky C, Kerr D, Whitmore W, Oettgen H. Treatment of superficial bladder cancer with intravesical BCG. Proc Amer Soc Clin Oncol 1980; C-160: 356
  • 20
    Cookson MS, Herr H, Zhang Z-F, Soloway S, Sogani P, Fair W. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 627
  • 21
    Herr H, Pinsky C, Whitmore W, Oettgen H, Melamed M. Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 1983; 51: 13236
  • 22
    Herr H, Sogani P, Pinsky C, Oettgen H, Whitmore W, Melamed M. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumours. Urology 1985; 25: 11923
  • 23
    Herr H, Pinsky C, Whitmore W, Sogani P, Oettgen H, Melamed M. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 2657
  • 24
    Herr H, Laudone V, Badalament R et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 14505
  • 25
    Herr H, Schwalb D, Zhang Z-F et al. Intravesical bacillus Calmette-Guerin therapy prevents tumour progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 14048
  • 26
    Lamm D, Thor D, Harris S, Reyna J, Stogdill V, Radwin H. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124: 3842
  • 27
    Lamm D, Thor D, Winters W, Stogdill V, Radwin H. BCG immunotherapy of bladder cancer: Inhibition of tumour recurrence and associated immune responses. Cancer 1981; 48: 828
  • 28
    Lamm D, Thor D, Harris S, Stogdill V, Radwin H. Intravesical and percutaneous BCG immunotherapy of recurrent superficial bladder cancer. In TerryW, RosenbergS eds, Immunotherapy of Human Cancer. North Holland: Elsevier, 1982: 31522
  • 29
    Lamm D, Thor D, Stogdill V, Radwin H. Bladder cancer immunotherapy. J Urol 1982; 128: 9315
  • 30
    Pagano F, Bassi P, Milani C et al. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results. In DebruyneF, DenisL, Van Der MeijdenA eds, EORTC Genitourinary Group Monographs 6, BCG in Superficial Bladder Cancer, New York: Alan R Liss Inc, 1989: 25361
  • 31
    Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 325
  • 32
    Pinsky C, Camacho F, Kerr D, Braun D, Whitmore W, Oettgen H. Treatment of superficial bladder cancer with intravesical BCG. In TerryW, RosenbergS eds, Immunotherapy of Human Cancer. North Holland: Elsevier, 1982: 30913
  • 33
    Rubben H, Graf-Dobberstein C, Ostwald R et al. Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs BCG Connaught vs TUR alone. InDeKernionJ, MazemanE eds, International Society of Urological Reports, Immunotherapy of Urological Tumours. New York: Churchill Livingstone, 1990: 2736
  • 34
    Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med 1998; 17: 281534DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8
  • 35
    Thompson RA, Campbell EW, Kramer HC, Jacobs SC, Naslund MJ. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 1993; 149: 10101
  • 36
    Lebret T, Gaudez F, Herve J-M, Barre P, Lugagne P-M, Botto H. Low dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success. Eur Urol 1998; 34: 762
  • 37
    Yalcinkaya F, Kamis L, Ozteke O, Gunlusoy B, Yigitbasi O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int Urol Nephrol 1998; 30: 414
  • 38
    Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 2724
  • 39
    Torti FM, Lum BL, Aston D et al. Superficial bladder cancer: The primacy of grade in the development of invasive disease. J Clin Oncol 1987; 5: 12530
  • 40
    Kurth KH, Denis L, Bouffioux CH et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 18406
  • 41
    Smith JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol 1999; 162: 1697701